BridgeBio Pharma (BBIO) Operating Expenses (2018 - 2026)

BridgeBio Pharma has disclosed Operating Expenses across 9 years of filings, most recently posting $300.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $300.5 million, up 35.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 33.92% YoY), and the FY2025 annual result was $1.0 billion, up 25.85% from the prior year.
• Operating Expenses came in at $300.5 million for Q1 2026 at BridgeBio Pharma, up from $293.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $300.5 million in Q1 2026 to a low of $128.0 million in Q1 2023.
• The 5-year median for Operating Expenses is $179.2 million (2023), against an average of $196.9 million.
• Across the five-year window, Operating Expenses decreased 27.02% in 2023 and surged 64.68% in 2024, its largest moves.
• BridgeBio Pharma's Operating Expenses stood at $131.1 million in 2022, then jumped by 36.66% to $179.2 million in 2023, then rose by 29.44% to $231.9 million in 2024, then rose by 26.66% to $293.7 million in 2025, then increased by 2.29% to $300.5 million in 2026.
• The last three Operating Expenses figures came in at $300.5 million (Q1 2026), $293.7 million (Q4 2025), and $265.9 million (Q3 2025), per Business Quant data.